The WWP2
E3 ubiquitin ligase has previously been shown to regulate TGFβ/Smad signalling activity linked to epithelial-mesenchymal transition (EMT). Whilst inhibitory I-Smad7 was found to be the preferred substrate for full-length WWP2-FL and a WWP2-C
isoform, WWP2-FL also formed a stable complex with an N-terminal WWP2
isoform (WWP2-N) in the absence of TGFβ, and rapidly stimulated activating Smad2/3 turnover. Here, using stable knockdown experiments we show that specific depletion of individual WWP2
isoforms impacts differentially on Smad
protein levels, and in WWP2-N knockdown cells we unexpectedly find spontaneous expression of the EMT marker
vimentin. Re-introduction of WWP2-N into WWP2-N knockout cells also repressed TGFβ-induced
vimentin expression. In support of the unique role for WWP2-N in regulating TGFβ/Smad functional activity, we then show that a novel V717M-WWP2 mutant in the MZ7-mel
melanoma cell line forms a stable complex with the WWP2-N
isoform and promotes EMT by stabilizing
Smad3 protein levels. Finally, we report the first analysis of WWP2 expression in
cancer cDNA panel arrays using WWP2
isoform-specific probes and identify unique patterns of WWP2
isoform abundance associated with early/advanced disease stages. WWP2-N is significantly downregulated in stage IIIC
melanoma and up-regulated in stage II/III
prostate cancer, and we also find isolated examples of WWP2-FL and WWP2-C overexpression in early-stage
breast cancer. Together, these data suggest that individual WWP2
isoforms, and particularly WWP2-N, could play central roles in tumourigenesis linked to aberrant TGFβ-dependent signalling function, and also have potential as both prognostic markers and molecular therapeutic targets.